Ghatak, Swagata
Dolatabadi, Nima
Gao, Richard
Wu, Yin
Scott, Henry
Trudler, Dorit
Sultan, Abdullah
Ambasudhan, Rajesh
Nakamura, Tomohiro http://orcid.org/0000-0002-4246-7771
Masliah, Eliezer
Talantova, Maria
Voytek, Bradley
Lipton, Stuart A.
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01 GM134363)
Article History
Received: 14 November 2019
Revised: 27 April 2020
Accepted: 1 May 2020
First Online: 29 May 2020
Compliance with ethical standards
:
: The authors declare that SAL is an inventor on worldwide patents for the use of memantine and NitroSynapsin for neurodegenerative and neurodevelopmental disorders. Per Harvard University guidelines, SAL participates in a royalty-sharing agreement with his former institution Boston Children’s Hospital/Harvard Medical School, which licensed the drug memantine (Namenda<sup>®</sup>) to Forest Laboratories, Inc./Actavis/Allergan, Inc. NitroSynapsin is licensed to EuMentis Therapeutics, Inc. The other authors declare that they have no conflict of interest.